REVIEW

New idea to promote the clinical applications of stem cells or their extracellular vesicles in central nervous system disorders: Combining with intranasal delivery

Yaosheng Li, Honghui Wu, Xinchi Jiang, Yunfei Dong, Juanjuan Zheng, Jianqing Gao

Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Regenerative Medicine, Zhejiang University, Hangzhou 310058, China
Hangzhou Institute of Innovative Medicine, Zhejiang University, Hangzhou 310058, China

Received 26 December 2021; received in revised form 27 January 2022; accepted 14 February 2022

Abstract The clinical translation of stem cells and their extracellular vesicles (EVs)-based therapy for central nervous system (CNS) diseases is booming. Nevertheless, the insufficient CNS delivery and retention together with the invasiveness of current administration routes prevent stem cells or EVs from fully exerting their clinical therapeutic potential. Intranasal (IN) delivery is a possible strategy to solve problems as IN route could circumvent the brain–blood barrier non-invasively and fit repeated dosage regimens. Herein, we gave an overview of studies and clinical trials involved with IN route and discussed the possibility of employing IN delivery to solve problems in stem cells or EVs-based therapy. We reviewed relevant researches that combining stem cells or EVs-based therapy with IN administration and analyzed benefits brought by IN route. Finally, we proposed possible suggestions to facilitate the development of IN delivery of stem cells or EVs.

© 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Because of the therapeutic potential in improving prognosis, stem cells and their extracellular vesicles (EVs)-based therapy is developing rapidly in the research and clinical application of central nervous system (CNS) diseases. In various CNS diseases, stem cells [e.g., mesenchymal stem cells (MSCs)] are found that can suppress the activation of neuronal cells, reduce the concentration of inflammatory cytokines and reactive oxygen species (ROS) in the microenvironment, and promote the regeneration of vessels and neurons. Paracrine is a vital pathway to realize the functions of stem cells. And as an important component of paracrine, EVs of stem cells are found to have similar functions. Furthermore, stem cells or EVs are observed would actively accumulate in the lesion site of the CNS diseases. Hence, stem cells or EVs can also serve as carriers for drug or gene delivery in CNS disorders treatment. Moreover, some progenitor cells could differentiate to replenish damaged or missing tissue in the lesion site. However, the blood–brain barrier (BBB) greatly restricts entry of most cells and vesicles into the brain. The complex mechanism involved in CNS disorders and the vulnerability of the CNS also increased the difficulties for treatment, the dose of stem cells or EVs is restrained and relapse of diseases is prone to happen. Therefore, further improvements to stem cells or EVs-based therapy are required to realize the therapeutic potential in clinical CNS disorder management.

The administration route directly influences the pharmacodynamics and pharmacokinetics of therapeutic agents. Different clinical occasions have additional demands for administration methods. And as active biologics, stem cells or EVs also have more requirements for delivery compared with traditional drugs. Therefore, discussion about the administration route of stem cells or EVs-based therapy in CNS disorder treatments is increasing in the recent five years. The intranasal (IN) route has a unique nose-to-brain pathway and shows many advantages when delivering biologics like protein and cells. In the past few years, studies that combined stem cells or EVs-based therapy with the IN route has increased rapidly in various fields of CNS disorder. However, there is no review available to systematically introduce the up-to-date status of the combination of IN route and stem cells or EVs-based therapy and conclude benefits IN route brought to stem cells or EVs-based therapy. Herein, we analyzed problems in stem cells or EVs-based therapy in clinical translation. We then discussed the feasibility and possible transportation route of IN delivering stem cells or EVs. We reviewed researches using IN administration for stem cells or EVs delivery and concluded multi-level benefits of the combination of IN route and stem cells or EVs-based therapy. The current limitations of the IN delivery for stem cells or EVs are also analyzed. Finally, we proposed several suggestions to facilitate the development of IN delivering stem cells or EVs.

2. Challenges for stem cells or EVs-based therapy in CNS disorders and opportunities for intranasal route

2.1. Troubles in clinical translation of stem cells or EVs-based therapy

Stem cells or EVs-based therapy has become a hot spot in many research fields due to their unique features. All sorts of stem cells, like MSCs, neural stem cells (NSCs), pluripotent stem cells, and along with EVs, have been used in different fields like wound healing, diabetes, arthritis, and especially, CNS diseases. Our previous studies found that engineered MSCs or NSCs could significantly diminish cerebral ischemia volume, reduce mortality rate, and promote motor function recovery in ischemic stroke. Similarly, in a spinal cord injury (SCI) model, we observed that MSCs and EVs promoted angiogenesis and neurogenesis in the lesion site and significantly improved behavioral performance of rats. In other reports, stem cells or EVs-based therapy could restore the deficit memory in Alzheimer’s disease (AD) models, rescue the loss of dopaminergic (DA) neurons in Parkinson’s disease (PD) models, normalize behavior in various psychiatric disorder models, and inhibit progress of brain tumors.

Encouraged by these results in animal models, clinical studies involved with stem cells or EVs also increased in recent years; some of them even proceeded into phase III of clinical trials. Table lists recent representative clinical trials of stem cells or EVs-based therapy.

However, most stem cells or EVs-based treatments are not approved for the clinical treatment of CNS disorders. Safety is a broad concern, yet most stem cell or EVs therapies did not show more adverse events in existing clinical and preclinical studies, even in the long-term Clinical trials of stem cells or EVs-based therapy that were withdrawn or terminated due to safety issues are not significantly higher than other studies. The source of stem cells or EVs is regarded as another problem, since the isolation and expansion of autologous stem cells commonly used in clinical trials are inconvenient and time-consuming. However, commercial allogeneic stem cells like Stempeucel® began available and used in clinical recently. These commercial cells could be a source in the future.

Lack of efficacy, however, seems to be a big problem for stem cells or EVs-based therapy in clinical translation. Many clinical results showed stem cells or EVs treatment strategies had no or limited effect on different CNS conditions. For examples, MSCs intravenous treatment had no or limited effect in ischemic stroke patients. Modified Rankin Scale (mRS), Barthel Index, and National Institute of Health Stroke Scale (NIHSS) showed no significantly improvement in months after MSCs administration. Although all the studies suggested application of MSCs in patients was safe. Failures are expected to appear as stem cells or EVs-based therapy is still in its early days of clinical research. We should find the reasons for the unsatisfied efficacy and solutions for the further development of stem cells or EVs-based therapy. Insufficient lesion site delivery and retention are possible reasons for the unsatisfied efficacy in the clinical trials of stem cells or EVs treatment. System administration is most often used in both preclinical and clinical studies of CNS diseases. However, many studies have pointed out that less than 1% of total stem cells or EVs could reach the lesion part. Most cells are trapped in small capillaries or retained in organs like the liver and lungs. The BBB would further prevent stem cells or EVs from entering the brain. Moreover, during the injection, the shear stress in syringe needles could damage stem cells or EVs. The interaction of blood components like complements and lymphocytes with exogenous objects could further influence the viability of stem cells or EVs. Therefore, stem cells or EVs that reached the lesion site may in a poor state and more vulnerable to the ROS, excitotoxicity, and activated immune cells in the lesion site’s harsh microenvironment. As a result, few stem cells or EVs could retain
in the lesion site after reaching. Research showed few days after intralesional administration, a rapid decrease in the number of stem cells happened in the lesion site. Although even the small percentage of stem cells or EVs remained is enough to treat animal models, patients' primary physiological conditions and regenerative capacity is not as good as model animals and need a higher lesion delivery and retention. Therefore, increasing lesion site delivery efficiency and retention could help to improve the efficacy of stem cells and EV therapy in clinical.

The invasiveness and dose frequency are other possible reasons. A high-invasive administration approach may not be tolerable by CNS patients. Embolism, infection, and trauma could happen during administration. Although intra-cerebroventricular infusion is regarded as a safe way for long-term administration, infection and other adverse events are still often reported. Therefore, currently single-dose or doses with long-interval of stem cells or EVs are commonly used to reduce adverse events in patients. Table 1 lists representative stem cells and EVs treatment regimens in clinical trials. But some CNS diseases are progressive or would recurrent, frequent dosage may help to achieve long-term relief. Researches showed that rescue in behavioral performance after single administration could start to diminish in days after administration in some CNS disorders. Therefore, repeated dosage delivered non-invasively may be a better choice for stem cell and EV therapy.

In a word, 1) insufficient lesion site delivery, 2) retention and 3) patient tolerance to multi-dose regimens are serval factors that influence the clinical performance of stem cells or EVs-based therapy. To overcome the above problems, finding a more suitable delivery approach for stem cells or EVs-based therapy should be the most direct and economical solution. A new administration approach that could improve pharmacokinetics and could increase the tolerance of CNS disorder patients to multi-dose may help to better realize the therapeutic potential of stem cells or EVs-based therapy.

### 2.2. The potential of intranasal administration in CNS disorder treatment

In recent years, IN administration is getting increasing attention due to the unusual transport pattern. Special histological features in some nasal cavity regions enable direct access of drugs most areas of the CNS after IN administration is possible. The olfactory sensory neurons in the olfactory area of the nasal cavity and two branches of the trigeminal nerve in the respiratory region of the nasal cavity have free nerve terminals under the mucosa. Therefore, the drug can pass through the epithelium and reach the olfactory bulb or pons along the axons. Then the drug can enter the perivascular space of the cerebrovascular or spread with the cerebrospinal fluid, and finally, distributed throughout the CNS.

As the IN route could bypass the BBB and avoid the first-pass effect, IN route is used for drugs that have difficulties reaching the brain. Special histological features in some nasal cavity regions enable direct access of drugs. The olfactory sensory neurons in the olfactory area of the nasal cavity and two branches of the trigeminal nerve in the respiratory region of the nasal cavity have free nerve terminals under the mucosa. Therefore, the drug can pass through the epithelium and reach the olfactory bulb or pons along the axons. Then the drug can enter the perivascular space of the cerebrovascular or spread with the cerebrospinal fluid, and finally, distributed throughout the CNS.

As the IN route could bypass the BBB and avoid the first-pass effect, IN route is used for drugs that have difficulties reaching the brain. Special histological features in some nasal cavity regions enable direct access of drugs. The olfactory sensory neurons in the olfactory area of the nasal cavity and two branches of the trigeminal nerve in the respiratory region of the nasal cavity have free nerve terminals under the mucosa. Therefore, the drug can pass through the epithelium and reach the olfactory bulb or pons along the axons. Then the drug can enter the perivascular space of the cerebrovascular or spread with the cerebrospinal fluid, and finally, distributed throughout the CNS.

### Table 1: Representative clinical trials of stem cells or EVs based therapy in CNS diseases.

| Condition          | NCT number          | Phase         | Intervention                                                                 | Status   | Ref. |
|--------------------|---------------------|---------------|------------------------------------------------------------------------------|----------|-----|
| Ischemic stroke    | NCT03545607         | Phase III     | Single intravenous infusion of multipotent adult progenitor cells             | Recruiting | 4   |
|                    | NCT03384433         | Phase II      | Intraparenchymal injection of allogenic MSCs derived exosome                 | Recruiting | N/A |
|                    | NCT01716481         | Phase III     | Single intravenous administration of autologous MSCs                        | Unknown  | 59  |
| Alzheimer’s disease| NCT02054208         | Phase II      | Repeated intraventricular administrations of MSCs via an ommaya reservoir    | Completed | 60  |
|                    | NCT04388982         | Phase II      | Repeated IN administrations of MSCs-Exos twice a week for 12 weeks           | Recruiting | N/A |
| Parkinson’s disease| NCT04506073         | Phase II      | Repeated administrated allogeneic MSCs every 3 months for three doses       | Recruiting | N/A |
| Multiple sclerosis | NCT04047628         | Phase III     | Repeated intrathecal or intravenous administration of autologous MSCs at six-month interval for 2 doses | Completed | 47  |
| Spinal cord injury | NCT02302157         | Phase II      | Single intralesional administration of oligodendrocyte progenitor cells      | Completed | N/A |
|                    | NCT04520373         | Phase II      | Single intrathecal administration of autologous MSCs                         | Recruiting | N/A |
| Neonatal stroke    | NCT0356821          | Phase II      | Repeated IN administration of allogeneic MSCs twice within the first week of onset | Completed | N/A |

Resource of the clinical trial is from ClinicalTrials.gov.

MSCs, mesenchymal stem cells; IN, intranasal; MSCs-Exos, mesenchymal stem cell derived exosomes; N/A, not applicable.
feasible to achieve therapeutic drug concentrations in the CNS compared with systematic injection.

The drug delivery of IN route is non-invasive. IN-delivery devices like spray, atomization, nose drop, or other devices have relatively simple administrative procedures and would not cause extra harm to the patients. Therefore, patients could tolerant high-frequency IN administration. Repeated IN delivery in a week, even in a day, is commonly found in clinical trials involved with IN administration, as presented in Table 2. With the assist of administration devices, self-administration is also available for patients, which reduces the influence of the frequent dosage on patient life. Therefore, IN route could enable flexible regimens that have different treatment courses and frequencies for CNS management.

The advantages of IN delivery in pharmacokinetics and therapeutic regimen guarantee its benefit in efficacy. IN delivery of nerve growth factors (NGF), insulin, oxytocin, erythropoietin, and other drugs have shown promising effects in various CNS disease models. Clinical trials using the IN route for drugs delivery are also emerging in recent years, Table 2 lists the representative clinical trials using IN delivery for CNS disorder treatment. The IN delivery is applied on various clinical occasions and could be used for the elderly or children in clinical trials. Better prognosis and long-term relief were also observed in many clinical trials compared with intravenous administration.

Overall, IN delivering drugs could improve pharmacokinetic, increase patient tolerance and enable flexible multi-dose therapeutic regimens. However, there is less discussion about IN delivery of stem cells or EVs. If these advantages of the IN pathway can also be found when delivering stem cells or EVs, it may compensate for the problems in stem cells or EVs-based therapy. IN pathway would be a possible way to facilitate the clinical translation of stem cell and EV therapy.

2.3. The transportation process of stem cells or EVs in the intranasal pathway

IN route mostly was used for the delivery of drugs or proteins with a relatively small size (less than tens of nanometers). The transport capacity of IN route for larger particles has been found only recently. Epithelium in the olfactory and respiratory region is the first barrier for large particles transportation. Researchers showed in the olfactory epithelium, the resident basal cell would differentiate and replace sustentacular cells or olfactory sensory neurons. The ciliated and goblet cells in the respiratory epithelium also would undergo similar replacement. The process of turnover of cells in the nasal epithelium results in discontinuous tight junctions and a higher permeability. Furthermore, lipid nanoparticles were found could transiently open the tight junctions in the nasal epithelium, which means nasal epithelium is more permeable to particles with lipid surfaces. Besides paracellular bypass the epithelial barrier, nanoparticles including lipid nanoparticles also could cross the epithelium through transcytosis. EVs of stem cells have similar size and surface properties as lipid nanoparticles, a similar transport pattern to cross epithelium may be adapted to EVs. The inflammation tropism ability of stem cells or EVs is also important in the trans-epithelial migration. Stem cells or EVs could interact with epithelial cells and cause a cytoskeletal reorganization of epithelial cells, which makes stem cells or EVs capable to overcome the barrier. This process is mediated by chemokine gradients and could be augmented under inflammation states. Researchers found the presence of stem cells or EVs in the submucous space after IN delivery, the number of cells or EVs would increase under pathological conditions. These findings support the inflammation tropism of stem cells or EVs that could facilitate trans-epithelial migration.

The cribriform plate is another barrier for nose-to-brain transportation through the olfactory nerve pathway. The small molecular could cross the cribriform plate intracellularly by the axonal transport of olfactory sensory neurons. And olfactory ensheathing cells in the olfactory nerve bundle maintain continuous open spaces for the regrowth of olfactory nerve fibers, creating an extracellular path (within the nerve bundle) to cross the cribriform plate. Only loaded cargos could be released and enter the brain region. Intact nanoparticles with a

| Condition                  | NCT number  | Phase  | Intervention                                         | Status    | Ref. |
|----------------------------|-------------|--------|-----------------------------------------------------|-----------|-----|
| Alcoholism                  | NCT03339024 | Phase III | Repeated IN administration of oxytocin spray twice a day for 30 days | Completed | 93  |
|                            | NCT01829516 | Phase IV | Single IN administration of oxytocin                  | Completed | N/A |
| Schizophrenia               | NCT00575666 | Phase IV | Repeated IN administration of insulin 4 times a day   | Completed | N/A |
|                            | NCT03245437 | Phase IV | Oxytocin nasal spray                                 | Completed | N/A |
|                            | NCT01767909 | Phase II/III | Daily IN administration of insulin for 12 months     | Completed | N/A |
| Treatment-resistant depression | NCT02497287 | Phase III | Repeated IN self-administration of esketamine twice a week for 4 weeks | Completed | 81  |
| Ischemic stroke             | NCT03686163 | Phase IV | Daily IN administration of NGF for 2 weeks           | Completed | N/A |
| Epilepsy                    | NCT01999777 | Phase III | Single IN administrated of midazolam                  | Completed | 95  |

Resource of the clinical trial is from ClinicalTrials.gov. IN, intranasal; NGF, nerve growth factor; N/A, not applicable.
size of ~100 nm could be detected in the trigeminal nerve tract, and
these nanoparticles could reach the brain stem through the trigeminal
nerve pathway\textsuperscript{109}. But as the size increases to ~1000 nm, intact
nanoparticles are no longer able to reach the brain stem through the
trigeminal nerve pathway in a short time\textsuperscript{110}. Therefore, it seems hard
for stem cells ($10^{-20} \text{mm}$) and EVs ($100-1000 \text{nm}$) to reach the
brain especially through olfactory nerve pathways. Yet a quick
localization in the olfactory bulb of stem cells or EVs after IN
administration was confirmed by many studies\textsuperscript{111,112}. Using MRI
tracking, a dynamic transfer from the nasal region to the olfactory
bulb could also be observed\textsuperscript{113-115}. These articles suggest that
stem cells or EVs appear to travel along with the olfactory nerve
bundles (Fig. 1). Detailed analysis showed the signal of stem cells is
just adjacent to, but not within, the olfactory nerve bundles, which is
different from the known olfactory nerve pathway\textsuperscript{84} (Fig. 1). These
findings imply stem cells or EVs may employ a novel route crossing
the cribiform plate. Immune cells like T cells and monocytes could
be observed crossing the cribiform plate from the CNS to the nasal
region. When crossing the cribiform plate, immune cells are also
found adjacent to the olfactory nerve yet not within the nerve bundle,
just like stem cells entering the CNS\textsuperscript{116-118}. Therefore, there is a
hypothesis that stem cells or EVs may enter the CNS following the
reverse route used by immune cells. The cytokine concentration
gradients may drive the trans-cribriform plate movement of stem
cells or EVs. Research showed that increasing the concentration of
SDF-1 (ligand of CXCR4) in the brain could increase the number of
stem cells entering the brain for serval-fold, which supports the hy-
pothesis\textsuperscript{108,117}. The cerebrospinal fluid also exits from the brain
through the cribiform plate and enters the nasal area unidirectional-
ly, suggesting the hypothesis is histologically feasible\textsuperscript{118}. Yet the
pressure gradient between the nasal cavity and the CNS could be a
barrier, the stem cells or EVs need to overcome the relatively higher
pressure in the cerebral. Hence active migration ability may be
necessary to enter the CNS through this hypothesis pathway, which
explains why nanoparticles cannot enter the brain through this hy-
pothetical pathway.

In a word, the inflammation tropism of stem cells or EVs play
an important role in crossing the epithelium and cribiform plate
barrier. Stem cells or EVs may have a unique transport pattern to
reach the brain compared with small molecules and nanoparticles.
The detailed mechanism of the transport route of stem cells or
EVs still needs further exploration.

3. Benefits of combining stem cells or EVs-based therapy
with intranasal route

3.1. Intranasal route increased lesion site distribution of stem
cells or EVs

Since insufficient lesion site delivery is a problem for stem cells or
EVs-based therapy, there are growing studies trying to improve
the targeting ability of stem cells or EVs. Modification of stem cells or EVs such as hypoxic treatment\(^\text{19}\), iron oxide nanoparticle stimulation\(^\text{8,120}\), and C-X-C chemokine receptor type 4 (CXCR4) overexpression\(^\text{121}\) was employed to enhance the CNS lesion site targeting and improve treatment effect in preclinical studies. Our study had shown that iron oxide nanoparticle stimulation could increase MSCs distribution in the cerebral ischemia site. Reduced mortality rate and improved motor recovery were observed in MCAO mice\(^\text{6}\). But the engineering of stem cells or EVs would increase the difficulties in quality control and the complexity in manufacture. In contrast, the IN route is a more straightforward solution. Table 3\(^\text{122–131}\) lists the representative pharmacokinetic data of IN administration of stem cells or EVs.

Gliomas treatment have difficulties in realizing enough drug concentration at the tumor site\(^\text{132,133}\). IN delivery of engineered MSCs or NSCs both showed a selective accumulation at the tumor site and better tumor penetration (Table 3). The high distribution of engineered MSCs or NSCs at tumor site also helped to extend survival time in primary tumor tissue grafted rats\(^\text{14,17,134,135}\). Pretreated nasal cavity with methimazole, drugs could delay the nasal clearance and enhance epithelium penetration, further promoting tumor site delivery of stem cells. Studies have shown that methimazole treatment increased the oncolytic virus-loaded NSC distribution at the tumor site after IN delivery to 20% and prolonged the survival time of rats\(^\text{18}\). The above studies showed that IN administration was effective to increased tumor accumulation and to boost the efficacy of stem cells or EVs treatment in brain tumors.

In an aged αSyn transgenic PD model, seven days after administration, MSCs were found that accumulated in the striatum where the loss of dopaminergic (DA) neurons happened\(^\text{136}\). In a 6-OHDA induced PD model rats. IN delivery of human olfactory ecto-mesenchymal stem cells (OE-MSCs) show a comparable graft rate and even better therapeutic effect in DAergic markers rescue and motor function improvement compared with direct injection into the striatum\(^\text{137,138}\). These findings proved IN administration could also achieve a high CNS delivery efficiency in PD models.

For other diseases without a specific lesion part like AD. After IN administration, EVs are distributed in various brain areas, not limited to the olfactory bulb\(^\text{111}\). The EVs seem firstly migrate to the immature olfactory sensory neurons and then migrate along with the axon to the CNS. The intrinsic inflammation tropism (homing) ability of EVs may promote EVs to pass through the epithelium and increase the delivery efficiency. The high graft rate of EVs in the brain help to achieve robust neuroprotection, remarkable neurogenesis, and rescue of memory deficits in App/Ps1 transgenic mice\(^\text{31,79,139,140}\). Furthermore, IN administration of EVs also

| Table 3 | Representative pharmacokinetic data of IN administration of stem cells or EVs in different models. |
|---------|-----------------------------------------------------------------------------------------------|
| Model | Pharmacokinetic data | Ref. |
| AD model mice | EVs were detected in the brainstem and olfactory bulb firstly at 0.25 h and reaching a peak at 1 h. | 41 |
| PD mice | Stem cells were detected in the whole brain area 7 days after administration. The brainstem and olfactory bulb contain the most cells (~20 %, respectively). | 79 |
| PD model rats | Stem cells were detected in the whole brain region and most distributed in the striatum and substantia nigra 2 months after administration. | 122 |
| AD model mice | Stem cells were detected in the olfactory bulb, hippocampus, ventral and dorsal cortex, brain splits, thalamus, and cerebellum 4 months after administrations. | 123 |
| Neonatal brain injury model rats | 24 h after administration, stem cells were detected in the corpus callosum, cerebral cortex, olfactory bulb, and hippocampus. | 124 |
| SCI model of rats | Stem cells were detected in the lesion site of the spinal cord 2 and 4 weeks after the administration. Compared with 2 weeks ago, the number of MSCs in the lesion site even increased 4 weeks after administration. | 125 |
| SCI model rats | Exosomes were mainly detected in the lesion part of the spinal cord at 24 h after administration. The number of exosomes in the spinal cord even exceeds the brain. | 126 |
| Neonatal brain injury model mice | Stem cells were mainly detected in the brain at 12 h after administration. | 127 |
| Stroke model mice | Exosomes were mostly detected in the lesion hemisphere 1 or 24 h after administration. Number of exosomes in the ischemic part increasing overtime. | 128 |
| Glioblastoma model mice | Stem cells were mostly detected at the tumor site at 6 h after administration. The number of stem cells reached a peak at 24 h and remained steady in 5 days. | 111 |
| Glioma model mice | Stem cells were detected in the tumor area at 1 h, and the number of stem cells significantly decreased on day 5 but remained steady by Day 11; distribution of stem cells in the brain of irradiated animals was 2.8 times higher. | 117 |
| Glioma model mice | Stem cells were detected in the brain at 2h, reached a peak at day 1, and slightly decreased by Day 6. | 129 |
| Glioma model mice | Stem cells were detected in the tumor area at 24 h but reached a peak at 120 h after administration when treated with methimazole and fibrin glue. | 18 |
| Bbr T+Ipsy3ff/J (Bbr) mice | Exosomes were detected in the brain at 24 h after administration. | 130 |
| EAE model mice | Secretome of amnion-derived multipotent progenitor cells (ST266) was selectively accumulated in the optic nerve and vitreous at 30 min after administration. | 44 |
| Chronic alcohol consumption model rats | Exosomes were detected in the brain at 2 h and gradually increased within 24 h after administration. | 131 |
| Status epilepticus model mice | Exosomes were detected in the cortical and hippocampal at 6 h after administration. | 14 |

AD, Alzheimer’s disease; EVs, extracellular vesicles; PD Parkinson’s disease; MSCs, mesenchymal stem cells; SCI, spinal cord injury; EAE, experimental autoimmune encephalomyelitis.
showed efficacy in aged App/Ps1 AD mice, whereas intravenous delivery failed to ameliorate symptoms. The poor basic physical conditions account for the lack of efficacy in elderly mice, which is also one of the reasons for the failure of stem cells or EVs treatment in elderly patients. The better effectiveness of IN delivery in elderly mice suggests that IN route could better exhibit the curative effect of EVs-based therapy.

In cases of acute neuroinflammation disease where barrier function of BBB partly breaks down, stem cells or EVs could be detected in the lesion part within an hour after IN administration (Table 3). In a stroke model, the fast delivery of stem cells or EVs ameliorated post-ischemic events, a reduced infarct area and inflammation were observed, and junctions of vascular were well persevered after treatment. In perinatal brain injury models, a similar fast delivery to the brain was also observed in rat pups. NSCs or exosomes of MSC reached the brain in hours. The immediate intervention significantly rescued motor and cognitive development of pups who received stem cells or EVs-based therapy. Even in spinal cord injury models where cognitive development of pups who received stem cells or EVs-based therapy, the transplantation of scaffold needs surgery and is prolonged the retention of MSCs and EVs in the lesion site of SCI. The quick entry of stem cells or EVs into the CNS enabled by IN administration could help to seize the treatment window, which is quite meaningful for the viability. In glioma models the number of stem cells in tumor site could remain steady or with mild decrease for in a week. Methimazole treatment before administration, the signal of NSCs showed efficacy in aged App/Ps1 AD mice, whereas intravenous delivery failed to ameliorate symptoms. The poor basic physical conditions account for the lack of efficacy in elderly mice, which is also one of the reasons for the failure of stem cells or EVs treatment in elderly patients. The better effectiveness of IN delivery in elderly mice suggests that IN route could better exhibit the curative effect of EVs-based therapy.

IN route could prevent the damage to stem cells or EVs caused in syringe needles. And stem cells or EVs would be directly transported into the brain but not immediately into the lesion site after IN administration, which also helps maintain the viability. In glioma models the number of stem cells in tumor site could remain steady or with mild decrease for in a week. Methimazole treatment before administration, the signal of NSCs showed efficacy in aged App/Ps1 AD mice, whereas intravenous delivery failed to ameliorate symptoms. The poor basic physical conditions account for the lack of efficacy in elderly mice, which is also one of the reasons for the failure of stem cells or EVs treatment in elderly patients. The better effectiveness of IN delivery in elderly mice suggests that IN route could better exhibit the curative effect of EVs-based therapy.

IN route could prevent the damage to stem cells or EVs caused in syringe needles. And stem cells or EVs would be directly transported into the brain but not immediately into the lesion site after IN administration, which also helps maintain the viability. In glioma models the number of stem cells in tumor site could remain steady or with mild decrease for in a week. Methimazole treatment before administration, the signal of NSCs showed efficacy in aged App/Ps1 AD mice, whereas intravenous delivery failed to ameliorate symptoms. The poor basic physical conditions account for the lack of efficacy in elderly mice, which is also one of the reasons for the failure of stem cells or EVs treatment in elderly patients. The better effectiveness of IN delivery in elderly mice suggests that IN route could better exhibit the curative effect of EVs-based therapy.

Combination with radiotherapy also showed improved distribution and retention of MSCs, the number of MSCs at tumor site remained steady from Day 5 to Day 11 after administration. As irradiation could upregulate the CXCL12 expression in tumor site, the inflammation tropism ability of stem cells may also involve in the improved retention. Similarly, in experimental autoimmune encephalomyelitis (EAE) models, IN delivery showed a superior in lesion site retention compared with intraperitoneal or intravenous injection and CXCR4 overexpression further enhanced retention of MSCs. In 6-OHDA-induced PD model, stem cells or EVs were found to gradually accumulate to the striatum and substantia nigra, stem cells or EVs could still be observed months after administration. Meanwhile, the stem cells or EVs in other brain regions, like the olfactory bulb or brainstem, were constantly decreased after administration. These findings proved that stem cells or EVs would continuously migrate from other brain regions (mainly the olfactory bulb) to the lesion site even weeks after administration. In SCI models, though the lesion site is far from the brain, the migration of stem cells is still found 4 weeks after administration.

IN route as a reservoir for stem cells or EVs, as the olfactory bulb is the first stop for a major part of stem cell IN delivered. Stem cells or EVs in the olfactory bulb are slowly migrate to the lesion part in the CNS that helps maintain the number of cells or EVs in the lesion part. And the inflammation tropism ability of stem cells or EVs seems to be the main driving force for the migration. In healthy mice or rats, stem cells or EVs delivered through IN route were found to linger in the olfactory bulb for a longer time and would have universal distribution in brain, lungs and liver, which also proved the reservoir function of the olfactory bulb. These findings suggest the special transport pattern of IN route contribute to the longer retention (Fig. 3).

**Figure 2** Lesion site targeting of stem cells and EVs after IN administration. Stem cells or EVs migrate along the olfactory sensory neurons or trigeminal nerve and directly enter the olfactory bulb or brainstem. More stem cells or EVs could reach the CNS as these routes could bypass the BBB. Then they would gradually migrate to the lesion site in the CNS, achieving a higher distribution here.
In a word, IN route better preserved the viability of stem cells or EVs, and the olfactory bulb may serve as a reservoir that could sustain release of stem cells or EVs and maintain the number of stem cell and EVs in the lesion site. Hence, IN route could also be an answer for the insufficient lesion site retention in stem cells or EVs-based therapy.

3.3. Non-invasive procedures of intranasal route enable multidose and flexible regimen

There is a dilemma for CNS treatment: the less invasive intravenous route has unsatisfying lesion delivery; while high transplant efficient topical CNS injection is not tolerable by patients especially when repeated administration. In contrast, IN route could balance the delivery efficiency and patient tolerance. Therefore, multi-dosage of IN administration of stem cells or EVs could be the answer to the conflict, and it may be more effective and safer for CNS disease treatment.

Repeated IN delivery of MSCs and EVs caused no inflammation in the short-term; nor was there any behavioral abnormalities or histological changes in the long term. Mouse, rat, and pig pups of neonatal brain injury model showed good tolerance to IN administration of stem cells or EVs. A clinical trial also has used two doses of IN administration of 5 × 10^7 MSCs to treat neonates suffering from perinatal arterial ischemic stroke (NCT03356821). Therefore, IN delivery of stem cells or EVs is patient-friendly and is tolerable even for infants.

The more frequent dosage enabled by IN route appears to be beneficial for CNS disorder treatment (Table 4). In a perinatal asphyxia model, the additional dosage of MSCs secretome seven days after modeling dose seems further improve the locomotor activity, recognition memory, and anxiety of mouse pups. In chronic diseases like neurodegeneration or EVs in the lesion site, the inhibition effect in ethanol intake began to decline 24 h after a single IV administration of MSCs-derived exosomes. Although single IN administration also only had a transient treatment effect, repeated administration of MSCs-derived exosomes had similar efficacy as a single intracranial injection of MSCs. Therefore, frequent repeated IN administration in a short period could also have a long-term effect, as indicated in (Fig. 4B). In the chronic alcohol intake model, the inhibition effect in ethanol intake began to decline 24 h after a single IV administration of MSCs-derived exosomes. Although single IN administration also only had a transient treatment effect, repeated IN administration within a month showed a more effective and long-lasting reverse in alcohol intake than single IV administration.

In summary, long-term regularly administration of stem cells or EVs or shot-term multiple IN administration of them both showed an impressive effect in different animal models.
| Model                             | Treatment regimen | Pharmacodynamic data                                                                 | Ref.  |
|----------------------------------|-------------------|----------------------------------------------------------------------------------------|-------|
| AD model mice                    | Once a day for 3 weeks | Pathology changes were ameliorated 2 days after treatment that is like a single intravenous injection of MSCs. | 139   |
| AD model mice                    | Once a week for 4 weeks | 7 days after treatment, the memory was fully restored in aged mice after repeated IN administration. Single IN or intravenous administration fails to rescue memory fully. | 79    |
| AD model mice                    | Every two days for 2 weeks | Pathology changes were ameliorated and behavioral performances were improved at the end of treatment. | 41    |
| AD model mice                    | Once a week for 4 weeks | Behavioral performances were significantly improved 2 months after administration, and pathology changes were ameliorated 3 months after treatment. | 123   |
| PD model rats                    | Single administration | Behavioral performances were improved one week after administration and the improvement remained to 4 weeks. | 147   |
| Ischemic stroke and refusion model mice | 1 h after modeling, twice a day for 7 days | Inflammation was inhibited and histological structure was restored at end of treatment. Behavioral performances were continuously improved during 7-days-treatment. | 141   |
| Neonatal brain injury model mice | A dose of MSCs administered 3, 10, or 17 days after modeling | Cognitive function improvement was achieved when administration at 3 or 10 but not 17 days after modeling. | 151   |
| Perinatal asphyxia model rats    | Two doses of exosomes administered 2 h and 7 days after modeling | Inflammation was inhibited, and motor function was improved after the first dose; further improvement in behavioral performances was found after the second dose. | 152   |
| Neonatal brain injury model mice | Single dose administered immediately after modeling | Inflammation and brain tissue volume loss were inhibited, and behavioral performances were improved 2 days after administration. | 143   |
| SCI model rats                   | A single dose administered 24 h after modeling | Significant behavioral performances improvement was only observed at day 7 after modeling. | 125   |
| SCI model rats                   | 2–3 days after modeling, once a day for five days | Behavioral performances were improved starting from 2 weeks after administration and a significant benefit was maintained to 8 weeks. Intralesional injection fails to improve behavioral performance. | 126   |
| Glioma model mice                | Irradiation for 5 days combined with IN delivery of MSCs once a week for 4 weeks | The survival of mice was improved. Combination with irradiation could further enhance the efficacy of stem cell transplantation. | 117   |
| Glioma model mice                | A single dose of NSCs administered after treating with methimazole and fibrin glue followed | The survival of mice was improved after stem cell transplantation. Methimazole and fibrin glue treatment could further enhance efficacy. | 18    |
| Chronic alcohol consumption model rats | Once a week for 5 weeks | Improvement in behavioral performances was achieved both after a single dose of IN or intracerebral exosomes, only repeated IN administration resulted in long-term relief. | 131   |
| Demyelination model mice         | Once a week for 12 weeks | Pathology changes were ameliorated and behavioral performances improved 30 days after treatment. | 146   |
| Btbr mice                        | Every two days for 8 days | Behavioral performances were improved 2 weeks after treatment. | 130   |

(continued on next page)
bioavailability of IN administration. Currently, nose drops are primarily used in both preclinical and clinical for stem cells or EVs-based therapy.

4. Future perspective for IN administration of stem cells or EVs-based therapy

As we discussed above, IN route showed many advantages over current used administration route: the IV route has a poor lesion site transplantation rate\(^ {16} \); the topical injection is highly invasive and the frequency of dosage in topical injection was constrained\(^ {17} \); other administration routes like intra-arterial (IA) or intraperitoneal injection (IP) also fail to realize high CNS delivery efficiency, and both are relatively invasive\(^ {161,162} \). On the contrary, IN route could provide a direct nose-to-brain delivery and a high brain graft rate for stem cells or EVs. The non-invasive trait of IN route also makes it more suitable for CNS disorder patients who need long-term intervention. Table 5 shows the comparison among different administration routes.

In recent years, several clinical trials have used IN administration of stem cells or EVs to treat CNS diseases, including PD, stroke, and neonatal brain injury. Table 6 lists representative clinical trials of stem cells or EVs delivered by IN route in recent years.

Nevertheless, the research on IN delivery of stem cells or EVs is still in its initial stage, and related researches still face some critical problems. The biggest problem is the relatively low bioavailability of IN route\(^ {164,165} \). Currently, nose drops are primarily used in both preclinical and clinical for stem cells or EVs delivery. Stem cells or EVs would be cleared out of the nasal cavity before across the epithelium. The effective area for direct nose-to-brain delivery only takes up 3%–10% of the surface area of the nasal cavity, stem cells or EVs may enter circulation rather than enter CNS across the epithelium. Therefore, only a part of stem cells or EVs could directly enter the brain.

The thermosensitive hydrogel could form in situ hydrogel after administration, reduce the clearance of the nasal cavity, fix stem cells or EVs in the olfactory region, and help increase the bioavailability of IN administration\(^ {166,167} \). Currently, chitosan\(^ {168,169} \) and poloxamer\(^ {166,170} \) are commonly used to prepare thermosensitive hydrogel. These materials show good biocompatibility and have been used in clinics. Hence the two materials could possibly aid the IN delivery of stem cells or EVs. Absorption enhancer is another strategy. There are a variety of compounds that could facilitate the absorption of IN administration. Among them, surfactants are an important category of absorption enhancers\(^ {171,172} \). It is worth noting that both chitosan and poloxamer have been reported to enhance the permeability of epithelium\(^ {173,174} \). Hence, chitosan or poloxamer thermosensitive hydrogel may also promote stem cell cells or EVs migration through the epithelium. Apart from surfactants, researchers showed that pretreated nasal cavity with fibrin glue could inhibit cilia’s movement and prevent the clearance of stem cells from the nasal cavity\(^ {175} \). Hyaluronidase is another commonly used penetration enhancer for stem cells or EVs delivery. Hyaluronidase could degrade hyaluronic acid in the extracellular matrix (ECM) and loosen up the epithelium, which help stem cells or EVs cross the epithelium barrier.

Another problem is that stem cells or EVs are unsuitable for the administration devices of IN delivery. IN-delivery devices can reduce drug loss during administration, promote deposition in correct region of nasal cavity, and enable self-administration. Currently, powder formulations or liquid formulations are primarily used in various IN administration devices\(^ {176} \). For example, the Bi-Directional™ Breath Powered® device of OptiNose company is used for drugs like oxytocin powder delivery (NCT02414503), LMA MAD Nasal™ of Teleflex company is used for dexmedetomidine liquid delivery (NCT02955732). Yet, stem cells or EVs may lose their biological activity during preparation, storage, or delivery of formulations. The current formulation preparation process needs to be modified, or new formulation are required to help stem cells or EVs adapt to the IN-delivery devices. Biomimetic mineralization is a possible strategy to protect stem cells. Artificial mineral coats would form a rigid and degradable inorganic shell on the cell surface after mineralization and increased the resistance of cells to the adverse environment\(^ {177} \). This technology may enable the preservation of stem cells in powders. Prepared stem cells into spheroids also could prolong the storage time. The research found that MSCs in spheroids could remain >90% viability under ambient conditions and still showed therapeutic effects in mouse colitis models\(^ {1,178} \). Since EVs of stem cells are not living cells, they may be easier to

### Table 4 (continued)

| Model                  | Treatment regimen                      | Pharmacodynamic data                                           | Ref. |
|------------------------|----------------------------------------|-----------------------------------------------------------------|------|
| Schizophrenia model mice | Once a day for 14 days                 | Behavioral performances were improved                           | 153  |
| EAE model mice         | Daily administration for 4 weeks        | Pathology changes were ameliorated, and behavioral performances were improved during treatment | 44   |
| SE model mice          | Two hours after modeling IN deliver of two doses of exosomes within 18 h | Inflammation was inhibited, and long-term protection of memory and cognitive function were achieved. | 14   |

AD, Alzheimer’s disease; EVs, extracellular vesicles; PD Parkinson’s disease; MSCs, mesenchymal stem cells; NSCs, neural stem cells; SCI, spinal cord injury; EAE, experimental autoimmune encephalomyelitis; SE, status epilepticus; IN, intranasal.
be prepared into powder formulations. Lyophilization with cryoprotectants could avoid aggregation of EVs and extend the storage time of EVs179. Mannitol180 and trehalose181,182 were effective cryoprotectants for EVs and may enable EVs to adapt to powder IN-delivery devices.

The in vivo animal models for the studies of intranasal delivery is also a problem. For future research on stem cells or EVs formulations or administration devices, evaluation of pharmacodynamics and pharmacokinetics in animal models is necessary. Rodents like rats and mice are the most commonly used animals for experiments, as rats and mice are genetically similar to humans and have similar pathological mechanisms to humans in many diseases. However, the histological structure of the rodent nasal cavity is very different from that of humans34 (Fig. 5). Rats and mice are obligate nasal breathers and have a more acute sense of smell. Therefore, the structure of the nasal passages of rats and mice is more complex and has a significantly higher surface area to volume ratio. The olfactory area of rats and mice accounts for 40%—50% of the total nasal surface area, while the human olfactory area accounts for only 10% of the nasal surface area 83,184 (Fig. 5). Mucociliary clearance is also different between rodents and human. The direction of mucociliary movement in human is backward towards the nasopharynx, opposite to the direction of mucociliary movement in rodents185. Furthermore, rodents have small nostrils, making the IN-delivery process cumbersome, and it’s also difficult for rodents to adapt to IN-delivery devices. These facts make the pharmacokinetics of drugs delivered through IN route quite different between rodents and human. Therefore, data from large animals are crucial for preclinical studies and IN formulation and device development. Monkeys have a nasal cavity structure closer to humans34,186. Administration devices such as atomizers are also have been used in monkeys187. But the experimental monkey is very difficult to obtain, and the cost could be unaffordable. Rabbit may be an ideal substitute for large animals. The ratio of rabbit olfactory region in total nasal cavity surface is ~15%188 (Fig. 5), which is close to human. Current research shows that compared with other animals such as sheep or mice, the bioavailability and absorption rate of the drug in rabbits after IN administration is closer to that of humans189,190. Therefore, in addition to research on small animals, it is also recommended to conduct preclinical research on the IN delivery of stem cells or EVs in large animals such as rabbits. Due to the vast difference in

**Table 5** Comparison among different administration routes for stem cells or EVs transplantation.

| Route | Invasiveness | Delivery efficiency | Process complexity | Bioavailability | Dosage frequency |
|-------|--------------|---------------------|--------------------|----------------|-----------------|
| IV    | ++           | +                   | +                  | ++++           | ++              |
| IC    | +++++        | ++++                | ++++               | +++           | +               |
| IA    | +++          | ++                  | ++++               | +++           | +               |
| IP    | ++           | +                   | ++                 | +++           | ++              |
| IN    | −            | +++                 | +                  | +             | +++             |

IV, intravenous; IC, intracranial; IA, intra-artery; IP, intraperitoneal; IN, intranasal.
the nasal cavity structure between rodents and humans, the data obtained on large animals will have more reference value for clinical translation.

5. Conclusions

Stem cells or EVs-based therapy brings hope to the treatment of various CNS diseases. Yet the clinical translation of stem cells or EVs is facing many challenges. From the recent clinical trials involved with stem cells or EVs-based therapy, we conclude 1) insufficient lesion site delivery, 2) retention and 3) patients' tolerance to multi-dose regimens are three problems in stem cells or EVs-based therapy. We suggest that utilizing IN route for the administration of stem cells or EVs could be a simple but effective solution. The feasibility of delivering stem cells or EVs through IN path have been proved in many articles, though the detailed mechanism is not entirely clear. In current in vivo preclinical studies, we summarized that IN route could improve the biodistribution and retention of stem cells or EVs in the lesion site of the CNS. A more frequent and flexible IN treatment regime also enhances the efficacy of stem cells or EVs.

Yet current preclinical works are mainly focused on verifying the effect of IN delivery on the stem cell and EVs-based therapy for the CNS treatment. Future studies may also need to pay attention to the development of stem cells or EVs formulation for IN delivery. Integrate stem cells or EVs in formulation like hydrogel could prolong mucus retention and increase bioavailability. And these formulations may also help stem cells or EVs to fit IN-delivery devices, which could further simplify the administration procedure and improve delivery efficiency. And for the clinical translation, more experiments in large animals would be necessary, especially considering the vast difference between humans and rodents in the nasal cavity. Experiments on large animals would help understand the influence of formulation on the pharmacokinetics, as the data from large animal is closer to humans. Large animals are also more suitable for IN administration devices. Hence there is still a lot to be improved for the IN delivery of stem cells or EVs. Anyway, despite the intranasal route is still a new approach for the delivery of stem cells or EVs, we believe that it shows great potential and may become a critical factor in promoting the clinical translation of stem cells and EVs-based therapy.

Acknowledgements

This work was supported by National Natural Science Foundation of China (81973252, 82003668), China Postdoctoral Science Foundation (2020M671771), Ten-thousand Talents Program of Zhejiang Province (2018R52049, China), Natural Science Foundation of Zhejiang Province (LQ21H300002, China), Fundamental Research Funds for the Central Universities (2021QNA7021, China).

Author contributions

Yaosheng Li collected related research article and wrote the manuscript. Honghui Wu revised the manuscript. Xinch Jiang revised the manuscript. Yunfei Dong revised the manuscript. Juanjuan Zhen revised the manuscript. Jianqing Gao provided the
idea and revised the manuscript. All of the authors have read and approved the final manuscript.

Conflicts of interest

The authors declare no conflicts of interest.

References

1. Lindvall O, Kokaiha Z. Stem cells for the treatment of neurological disorders. Nature 2006;441:1094–6.
2. Zhang ZG, Buller B, Chopp M. Exosomes-beyond stem cells for restorative therapy in stroke and neurological injury. Nat Rev Neurol 2019;15:193–202.
3. Muir KW, Bullers D, Willmot M, Sprigg N, Dixit A, Ward N, et al. Intracerebral implantation of human neural stem cells and motor recovery after stroke: multicentre prospective single-arm study (PISCES-2). J Neurol Neurosurg Psychiatry 2020;91:396–401.
4. Hess DC, Wechsler LR, Clark WM, Savitz SI, Ford GA, Chiu D, et al. Safety and efficacy of multipotent adult progenitor cells in acute ischemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2017;16:360–8.
5. Madrazo I, Kopyov O, Ávila-Rodríguez MA, Ostrosky F, Carrasco R, Kopyov A, et al. Transplantation of human neural progenitor cells (NPC) into putamina of Parkinsonian patients: a case series study, safety and efficacy four years after surgery. Cell Transplant 2019;28:269–85.
6. Huang B, Jiang XC, Zhang TY, Hu YL, Tabata Y, Chen Z, et al. Peptide modified mesenchymal stem cells as targeting delivery system transferred with miR-133b for the treatment of cerebral ischemia. Int J Pharm 2017;531:90–100.
7. Jiang XC, Xiang Ji, Wu HH, Zhang TY, Zhang DP, Xu QH, et al. Neural stem cells transplanted with reactive oxygen species-responsive polypelexes for effective treatment of ischemic stroke. Adv Mater 2019;31:e1807591.
8. Zhang TY, Li FY, Xu QH, Wang QY, Jiang XC, Liang ZY, et al. Ferrimagnetic nanochains-based mesenchymal stem cell engineering for highly efficient post-stroke recovery. Adv Funct Mater 2019;29:1900603.
9. Jia YL, Cao N, Zhai JH, Zeng Q, Zheng P, Su RY, et al. HGF mediates clinical-grade human umbilical cord-derived mesenchymal stem cells improved functional recovery in a senescence-accelerated mouse model of Alzheimer’s disease. Adv Sci (Weinheim) 2020;7:1903809.
10. McDonald CA, Djulianissaza Z, Petrami M, Paton MCB, Penny TR, Sutherland AE, et al. Intranasal delivery of mesenchymal stromal cells protects against neonatal hypoxic-ischemic brain injury. Int J Mol Sci 2019;20:2449.
11. Ha S, Park H, Mahmood U, Ra JC, Suh YH, Chang KA. Human adipose-derived stem cells ameliorate repetitive behavior, social deficit and anxiety in a VPA-induced autism mouse model. Behav Brain Res 2017;317:479–84.
12. Li LM, Zhang Y, Mu JF, Chen JC, Zhang CY, Cao HC, et al. Transplantation of human mesenchymal stem-cell-derived exosomes immobilized in an adhesive hydrogel for effective treatment of spinal cord injury. Nano Lett 2020;20:4298–305.
13. Thomi G, Surbek D, Haesler V, Joerger-Messerli M, Schoeberlein A. Exosomes derived from umbilical cord mesenchymal stem cells reduce microglia-mediated neuroinflammation in perinatal brain injury. Stem Cell Res Ther 2019;10:105.
14. Long QF, Upadhyta D, Hattangiady B, Kim DK, An SY, Shuai B, et al. Intranasal MSC-derived A1-exosomes ease inflammation, and prevent abnormal neurogenesis and memory dysfunction after status epilepticus. Proc Natl Acad Sci U S A 2017;114:e3536–45.
15. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJA. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011;29:341–5.
(MSCs) for knee osteoarthritis: repeated MSC dose and to hyaluronic acid in a controlled randomized phase II/II trial. *Stem Cells Transl Med* 2019;8:215–24.

37. Lee K, Xue Y, Lee J, Kim HJ, Liu Y, Tebon P, et al. A patch of detachable hybrid microneedle depot for localized delivery of mesenchymal stem cells in regeneration therapy. *Adv Funct Mater* 2020;30:2000086.

38. Koffler J, Choi SH, Lee JS, Kim HJ, Kim KN, Lee JE, et al. Feasibility and efficiency of intra-arterial administration of embryonic stem cell derived-mesenchymal stem cells in animal model of Alzheimer’s disease. *J Alzheimers Dis* 2020;76:1281–96.

39. Fathollahi A, Hashemi SM, Hoseini MHM, Tavakoli S, Farahani E, Yeganen F. Intransal administration of small extracellular vesicles derived from mesenchymal stem cells ameliorated the experimental autoimmune encephalomyelitis. *Int Immunopharmac* 2021;90:107207.

40. Ma XY, Huang M, Zheng MN, Dai CX, Song QX, Zhang Q, et al. ADSCs-derived extracellular vesicles alleviate neuronal damage, promote neurogenesis and rescue memory loss in mice with Alzheimer’s disease. *J Control Release* 2020;327:688–702.

41. Golia-Afari H, Salgado AJ, Teixeira FG. Mesenchymal stem cells-derived exosomes: a new possible therapeutic strategy for Parkinson’s disease?. *Cells* 2019;8:118.

42. Larthaveeasap A, Pathipati P, Ostrin S, Rajah A, Ferriero D, Gonzalez FP. Enhanced mesenchymal stromal cells or erythropoietin provide long-term functional benefit after neonatal stroke. *Stroke* 2021;52:284–93.

43. Khan RS, Dine K, Bauman B, Lorentsen M, Lin L, Brown H, et al. Intransal delivery of a novel annion cell secretome protects neuronal damage and preserves function in a mouse multiple sclerosis model. *Sci Rep* 2017;7:41768.

44. Yamanaka S. Pluripotent stem cell-based therapy-promise and challenges. *Cell Stem Cell* 2020;275:53–31.

45. Hirsch T, Rothenf T, Teig N, Bauer JW, Pellegrini G, De Rosa L, et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. *Brain* 2020;143:3574–88.

46. Upadhya D, Hattiangady B, Castro OW, Shuai B, Kodali M, Attaluri S, et al. Human induced pluripotent stem cell-derived MGE cell grafting after status epilepticus attenuates chronic epilepsy and comorbidities via synaptic integration. *Proc Natl Acad Sci U S A* 2019;116:287–96.

47. Adamia M, Cheng GM, Bobis-Wozowicz S, Zhao L, Kedracka-Krok S, Samanta A, et al. Induced pluripotent stem cell (iPSC)-derived extracellular vesicles are safer and more effective for cardiac repair than iPSCs. *Circ Res* 2018;122:296–309.

48. Khah M, Nickoloff E, Abramova T, Johnson J, Verma SK, Krishnamurthy P, et al. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction. *Circ Res* 2015;117:52–64.

49. Mazini L, Rochette L, Admou B, Amal S, Malka G. Hopes and limits of adipose-derived stem cells (ADSCs) and mesenchymal stem cells (MSCs) in wound healing. *Int J Mol Sci* 2020;21:1306.

50. Sneddon JB, Tang QZ, Stock P, Bluestone JA, Roy S, Desai T, et al. Stem cell therapies for treating diabetes: progress and remaining challenges. *Cell Stem Cell* 2018;22:810–23.

51. Wang LM, Huang SG, Li SM, Li M, Shi J, Bai W, et al. Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis patients: a prospective phase II/I study. *Drug Des Dev Ther* 2019;13:4331–40.

52. Li LM, Xiao B, Mu JF, Zhang Y, Zhang CY, Cao HC, et al. A MnO2 nanoparticle-dotted hydrogel promotes spinal cord repair via regulating reactive oxygen species microenvironment and synergizing with mesenchymal stem cells. *ACS Nano* 2019;13:14283–93.

53. Wang YL, Liu XS, Wang SS, Xue P, Zeng ZL, Yang XP, et al. Curcumin-activated mesenchymal stem cells derived from human umbilical cord and their effects on MPTP-mouse model of Parkinson’s disease: a new biological therapy for Parkinson’s disease. *Stem Cells Int* 2020;2020:4636397.

54. You MJ, Bang M, Park HS, Yang B, Jang KB, Yoo J, et al. Human umbilical cord-derived mesenchymal stem cells alleviate schizophrenia-relevant behaviors in amphetamine-sensitized mice by inhibiting neuroinflammation. *Transl Psychiatry* 2020;10:123.

55. Hong X, Fei GQ, Liu WJ, Ding J, Wang Y, Wang H, et al. Adipose-derived mesenchymal stem cells protect against CMS-induced depression-like behaviors in mice via regulating the Nf2/HO-1 and TLR4/NF-kB signaling pathways. *Acta Pharmacol Sin* 2020;41:612–9.

56. Li A, Zhang TY, Huang T, Lin MY, JF, Su YQ, et al. Iron oxide nanoparticles promote Cx43-overexpression of mesenchymal stem cells for efficient suicide gene therapy during glioma treatment. *Theranostics* 2021;11:8254–69.

57. Chung JW, Chang WH, Bang OY, Moon GJ, Kim SJ, Kim SK, et al. Efficacy and safety of intravenous mesenchymal stem cells for ischemic stroke. *Neurology* 2021;96:e1012–23.

58. Kim HJ, Chok KR, Jang H, Lee NK, Jung YH, Kim JP, et al. Intra-cerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: a phase I clinical trial. *Alzheimer’s Res Ther* 2021;13:154.

59. Trounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. *Cell Stem Cell* 2015;17:11–22.

60. Hallett PJ, Cooper O, Sadi D, Robertson H, Mendez I, Isacson O. Long-term health of dopaminergic neuron transplant in Parkinson’s disease patients. *Cell Rep* 2014;7:1755–61.

61. Kefalopoulou Z, Politis M, Piccini P, Mencacci N, Bhaita K, Jahnshahi M, et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. *JAMA Neurol* 2014;71:83–7.

62. Liang J, Zhang HY, Kong W, Deng W, Wang DD, Feng XB, et al. Safety analysis in patients with autoimmune disease receiving allo-genic mesenchymal stem cell infusions: a long-term retrospective study. *Stem Cell Res Ther* 2018;9:312.

63. Diez-Tejedor E, Gutiérrez-Fernández M, Martínez-Sánchez P, Rodríguez-Frutos B, Ruiz-Ares G, Lara ML, et al. Reparative therapy for acute ischemic stroke with allogeneic mesenchymal stem cells from adipose tissue: a safety assessment: a phase II randomized, double-blind, placebo-controlled, single-center, pilot clinical trial. *J Stroke Cerebrovasc Dis* 2014;23:2694–700.

64. Théj C, Balasubramanian S, Rengasamy M, Walvekar A, Swamyathan P, Raj SS, et al. Human bone marrow-derived, pooled, allogeneic mesenchymal stromal cells manufactured from multiple donors at different times show comparable biological functions in vitro, and in vivo to repair limb ischemia. *Stem Cells Res Ther* 2021;12:279.

65. Gupta PK, Dutta S, Kala S, Nekkanti M, Desai SC, Mahapatra SS, et al. Phase IV postmarketing surveillance study shows continued efficacy and safety of stempeucel® in patients with critical limb ischemia due to Buerger’s disease. *Stem Cells Transl Med* 2021;10:1602–13.

66. Jaillal A, Hormell M, Moisan A, Zelfiri TA, Favre-Wiki IM, Barbier-Guillot M, et al. Autologous mesenchymal stem cells improve motor recovery in subacute ischemic stroke: a randomized clinical trial. *Transl Stroke Res* 2020;11:910–23.

67. Zhang S, Lachance BB, Moiz B, Jia XF. Optimizing stem cell therapy after ischemic brain injury. *J Stroke* 2020;22:286–305.

68. Rodríguez-Frutos B, Otero-Ortega L, Gutiérrez-Fernández M, Fuentes B, Ramos-Cejudo J, Diez-Tejedor E. Stem cell therapy and administration routes after stroke. *Transl Stroke Res* 2016;7:378–87.

69. Schmuck EG, Koch JM, Centanni JM, Hacker TA, Braun RK, Eldridge M, et al. Biodistribution and clearance of human
Intranasal delivery promote clinical translation of stem cells or EVs

mesenchymal stem cells by quantitative three-dimensional cryo-imaging after intravenous infusion in a rat lung injury model. Stem Cells Transl Med 2016;5:1668–75.

Aguado BA, Malayaasmita W, Su J, Lampé KJ, Heilshorn SC. Improving viability of stem cells during syringing needle flow through the design of hydrogel cell carriers. Tissue Eng Part A 2012;18:806–15.

Mamidi MK, Singh G, Husin JM, Nathan KG, Sasidharan G, Zakaria Z, et al. Impact of passing mesenchymal stem cells through smaller bore size needles for subsequent use in patients for clinical or cosmetic indications. J Transl Med 2012;10:229.

Li Y, Feng J, Lin F. Local inhibition of complement improves mesenchymal stem cell viability and function after administration. Mol Ther 2016;24:1665–74.

Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, Fransson M, Piras E, Wang H, Burman J, Duprez I, Harris RA, et al. Wilson JG, Liu KD, Zhuo HJ, Caballero L, McMillan M, Fang XH, Santamaria G, Brandi E, Vitola PL, Grandi F, Ferrara G, Pischiutta F, Coles LD, Tuite PJ, O¨ z G, Mishra UR, Kartha RV, Sullivan KM, et al. Le Guellec S, Ehrmann S, Vecellio L.

Aguado BA, Mulyasasmita W, Su J, Lampe KJ, Heilshorn SC. Impact of passing mesenchymal stem cells through smaller bore size needles for subsequent use in patients for clinical or cosmetic indications. J Transl Med 2012;10:229.

Li Y, Feng J, Lin F. Local inhibition of complement improves mesenchymal stem cell viability and function after administration. Mol Ther 2016;24:1665–74.

Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, Fransson M, Piras E, Wang H, Burman J, Duprez I, Harris RA, et al. Wilson JG, Liu KD, Zhuo HJ, Caballero L, McMillan M, Fang XH, Santamaria G, Brandi E, Vitola PL, Grandi F, Ferrara G, Pischiutta F, Coles LD, Tuite PJ, O¨ z G, Mishra UR, Kartha RV, Sullivan KM, et al. Le Guellec S, Ehrmann S, Vecellio L.

Aguado BA, Mulyasasmita W, Su J, Lampe KJ, Heilshorn SC. Impact of passing mesenchymal stem cells through smaller bore size needles for subsequent use in patients for clinical or cosmetic indications. J Transl Med 2012;10:229.

Li Y, Feng J, Lin F. Local inhibition of complement improves mesenchymal stem cell viability and function after administration. Mol Ther 2016;24:1665–74.
extends survival in mouse model of glioma. Stem Cell Rep 2016;7:471–82.

109. Li Y, Wang CL, Zong SY, Qi JP, Dong XC, Zhao WL, et al. The trigeminal pathway dominates the nose-to-brain transportation of intact polymeric nanoparticles: evidence from aggregation-caused quenching probes. J Biomed Nanotechnol 2019;15:686–702.

110. Ahmad E, Feng YH, Qi JP, Fan WF, Ma YH, He HS, et al. Evidence of nose-to-brain delivery of nanoemulsions: cargoes but not vehicles. Nanoscale 2017;9:1174–83.

111. Reitz M, Demestre M, Sedlack J, Meissner H, Fiehler J, Kim SU, et al. Intranasal delivery of neural stem/progenitor cells: a noninvasive passage to target intracerebral glioma. Stem Cells Transl Med 2012;1:866–73.

112. Zhuang XY, Xiang XY, Grizzle W, Sun DM, Zhang SQ, Axtell RC, et al. Treatment of brain inflammatory diseases by delivering exosome-encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther 2011;19:1769–79.

113. Herman S, Fishel I, Offen D. Intranasal delivery of mesenchymal stem cells-derived extracellular vesicles for the treatment of neurological diseases. Stem Cell 2021;39:1589–600.

114. Kaminski M, Bechmann I, Kiwit J, Glumm J, et al. Intranasal delivery of neural stem cell-derived exosomes for the treatment of neurodegenerative diseases. J Leukoc Biol 2019;106:797–801.

115. Balyasnikova IV, Prasol MS, Ferguson SD, Han Y, Ahmed AU, Gutova M, et al. Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors. Mol Ther 2014;22:140–8.

116. Buchowicz B, Chen BS, Bidot S, Bruce BB, Newman NJ, Saindane AM, et al. Prediction of postoperative risk of raised intracranial pressure after spontaneous skull base cerebrospinal fluid leak repair. J Neuro Ophthalmol 2021;41:e490–7.

117. Kipnis J. Multifaceted interactions between adaptive immunity and the central nervous system. Science 2016;353:766–71.

118. Balyasnikova IV, Prasol MS, Ferguson SD, Han Y, Ahmed AU, Gutova M, et al. Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors. Mol Ther 2014;22:140–8.

119. Wei L, Fraser JL, Lu ZY, Hu XY, Yu SP. Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats. Neurol Sci 2012;33:635–45.

120. Kim HY, Kim TJ, Kang L, Kim YJ, Kang MK, Kim J, et al. Mesenchymal stem cell-derived magnetic extracellular nanovesicles for targeting and treatment of ischemic stroke. Biomaterials 2020;243:119942.

121. Park SA, Ryu CH,Kim SM, Lim JY, Park SL, Jeong CH, et al. CXCR4+transfected human umbilical cord-derived mesenchymal stem cells exhibit enhanced migratory capacity toward gliomas. Int J Oncol 2011;38:97–103.

122. Simorgh S, Alizadeh R, Shabani R, Karimzadeh F, Seidkhani E, Majidpoor J, et al. Olfactory mucosa stem cells delivery via nasal route: a simple way for the treatment of Parkinson disease. Neurotox Res 2021;39:598–608.

123. Lu MH, Ji WL, Chen H, Sun YY, Zhao XY, Wang F, et al. Intranasal transplantation of human neural stem cells ameliorates Alzheimer’s disease-like pathology in a mouse model. Front Aging Neurosci 2021;13:65603.

124. J.G, Liu M, Zhao XF, Liu XY, Guo QL, Guan ZF, et al. NF-E2 signaling is involved in the effects of intranasally engrafted human neural stem cells on neurofunctional improvements in neonatal rat hypoxic-ischemic encephalopathy. CNS Neurosci Ther 2015;21:926–35.

125. Nominoya K, Iwatsuki K, Ohnishi Y, Okhawa T, Yoshimine T. Intranasal delivery of bone marrow stromal cells to spinal cord lesions. J Neurosurg Spine 2015;23:111–9.

126. Guo SW, Perets N, Betzer O, Ben-Shaul S, Sheinin A, Michaelevski I, et al. Intranasal delivery of mesenchymal stem cell derived exosomes loaded with phosphatase and tensin homolog siRNA repairs complete spinal cord injury. ACS Nano 2019;13:10015–28.

127. Vaes JEG, van Kammen CM, Trayford C, van der Toorn A, Ruwhedel T, Benderz MJNI, et al. Intranasal mesenchymal stem cell therapy to boost myelination after encephalopathy of prematurity. Glia 2021;69:655–80.

128. Betzer O, Perets N, Angel A, Motiei M, Sadan T, Yaidid G, et al. In vivo neuroimaging of exosomes using gold nanoparticles. ACS Nano 2017;11:10883–93.

129. Soria B, Martin-Montalvo A, Aguilar Y, Mellado-Damas N, López-Beas J, Herrera-Herrera I, et al. Human mesenchymal stem cells prevent neurological complications of radiotherapy. Front Cell Neurosci 2019;13:204.

130. Perets N, Hertz S, London M, Offen D. Intranasal administration of exosomes derived from mesenchymal stem cells ameliorates autist-like behaviors of Brb- mice. Mol Autism 2018;9:57.

131. Ezquer F, Quintanilla ME, Morales P, Santapau D, Ezquer M, Kogan MJ, et al. Intranasal delivery of mesenchymal stem cell-derived exosomes reduces oxidative stress and markedly inhibits ethanol consumption and post-deprivation relapse drinking. Addict Biol 2019;24:994–1007.

132. Tang W, Fan WP, Lau J, Deng LM, Shen ZY, Chen XY. Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics. Chem Soc Rev 2019;48:2967–3014.

133. Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, et al. Challenges to curing primary brain tumours. Nat Rev Clin Oncol 2019;16:509–20.

134. Clavreul A, Pourbaghi-Masouleh M, Roger E, Lautram N, Montero-Menei CN, Menei P. Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal?. J Exp Clin Cancer Res 2019;38:135.

135. Yu D, Li G, Lesniak MS, Balyasnikova IV. Intranasal delivery of therapeutic stem cells to glioblastoma in a mouse model. J Vis Exp 2017;55845.

136. Danielyan L, Beer-Hammer S, Stolzing A, Schäfer R, Siegel G, Fabian C, et al. Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mice models of Alzheimer’s and Parkinson’s disease. Cell Transplant 2014;23(Suppl 1):S123–39.

137. Nandakumar S, Shahani P, Datta I, Pal R. Interventional strategies for Parkinson disease: can neural precursor cells forge a path ahead?. ACS Chem Neurosci 2012;3:735–94.

138. Alizadeh R, Boroujeni ME, Kamrava SK, Tehrani AM, Bagher Z, Heidari F, et al. From transcriptome to behavior: intranasal injection of late passage human olfactory stem cells displays potential in a rat model of Parkinson’s disease. ACS Chem Neurosci 2021;12:2209–17.

139. Harach T, Iannm F, Muller C, Duthileul N, Cheatham V, Zafferey V, et al. Administrations of human adult ischemia-tolerant mesenchymal stem cells and factors reduce amyloid beta pathology in a mouse model of Alzheimer’s disease. Neurobiol Aging 2017;51:83–96.

140. Losurdo M, Pedrazzoli M, D’Agostino C, Elia CA, Massenzio F, Bonati E, et al. Intranasal delivery of mesenchymal stem cell-derived extracellular vesicles exerts immunomodulatory and neuroprotective effects in a 3xtg model of Alzheimer’s disease. Stem Cells Trans Med 2020;9:1068–84.

141. Kalani A, Chaturvedi P, Kamat PK, Maldonado C, Bauer P, Joshua IG, et al. Curcumin-loaded embryonic stem cell exosomes restored neurovascular unit following ischemia-reperfusion injury. Int J Biochem Cell Biol 2017;79:360–9.

142. Thomi G, Joerger-Messerli M, Haesler V, Muri L, Surbek D, Schoerbelin A. Intranasally administered exosomes from umbilical cord blood-derived mesenchymal stem cells reduce hypoxia-ischaemia induced perinatal brain injury. J Neurosurg Spine 2019;41:1088–93.

143. Sisa C, Kholia S, Naylor J, Herrera Sanchez MB, Bruno S, Deregibus MC, et al. Mesenchymal stem cell derived extracellular vesicles reduce hypoxia-ischaemia induced perinatal brain injury. Front Physiol 2019;10:282.

144. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects.
Intranasal delivery promote clinical translation of stem cells or EVs

of intravenous thrombolyis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. *Lancet* 2014;384:1929–35.

145. Iwami K, Momota H, Natsume A, Kinjo S, Nagatani T, Wakabayashi T. A novel method of intracranial injection via the postglenoid foramen for brain tumor mouse models. *J Neurosurg* 2012;116:630–5.

146. Beigi Boroujeni F, Pasbakhsh P, Mortezaea K, Pirhajati V, Alizadeh R, Aryapour R, et al. Intranasal delivery of SDF-1α-pre-conditioned bone marrow mesenchymal cells improves remyelination in the cuprizone-induced mouse model of multiple sclerosis. *Cell Biol Int* 2020;44:499–511.

147. Simorgh S, Bagher Z, Farhadi M, Kamrava SK, Boroujeni ME, Namjoo Z, et al. Magnetic targeting of human olfactory mucosa stem cells following intranasal administration: a novel approach to Parkinson’s disease treatment. *Mol Neurobiol* 2021;58:3835–47.

148. Donega V, van Velthoven CT, Nijboer CH, Youssef SA, de Bruin A, Robertson NJ, Meehan C, Martinello KA, Avdic-Belltheus A, Bahadur S, Sachan N, Harwansh RK, Deshmukh R. Nanoparticlized Intranasal delivery promote clinical translation of stem cells or EVs.
179. Akers JC, Ramakrishnan V, Yang I, Hua W, Mao Y, Carter BS, et al. Optimizing preservation of extracellular vesicular miRNAs derived from clinical cerebrospinal fluid. Cancer Biomark 2016;17:125–32.

180. Mocchi M, Bari E, Marrubini G, Bonda AF, Perteghella S, Tartara F, et al. Freeze-dried mesenchymal stem cell-secretome pharmaceuticalization: optimization of formulation and manufacturing process robustness. Pharmaceutics 2021;13:1129.

181. Charoenviriyakul C, Takahashi Y, Nishikawa M, Takakura Y. Preservation of exosomes at room temperature using lyophilization. Int J Pharm 2018;553:1–7.

182. El Baradie KBY, Nouh M, O’Brien Iii F, Liu YT, Fulzele S, Eroglu A, et al. Freeze-dried extracellular vesicles from adipose-derived stem cells prevent hypoxia-induced muscle cell injury. Front Cell Dev Biol 2020;8:181.

183. Ali J, Ali M, Baboota S, Sahani JK, Ramassamy C, Dao L, et al. Potential of nanoparticulate drug delivery systems by intranasal administration. Curr Pharm Des 2010;16:1644–53.

184. Graff CL, Pollack GM. Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci 2005;94:1187–95.

185. DeSesso JM. The relevance to humans of animal models for inhalation studies of cancer in the nose and upper airways. Qual Assur 1993;2:213–31.

186. Harkema JR. Comparative pathology of the nasal mucosa in laboratory animals exposed to inhaled irritants. Environ Health Perspect 1990;85:231–8.

187. Saccone PA, Lindsey AM, Keeppe RA, Zelenock KA, Shao X, Sherman P, et al. Intranasal opioid administration in rhesus monkeys: PET imaging and antinociception. J Pharmacol Exp Ther 2016;359:366–73.

188. Johnson-Delaney CA, Orosz SE. Rabbit respiratory system: clinical anatomy, physiology and disease. Vet Clin North Am Exot Anim Pract 2011;14:257–66.

189. Lindhardt K, Bagger M, Andreasen KH, Bechgaard E. Intranasal bioavailability of buprenorphine in rabbit correlated to sheep and man. Int J Pharm 2001;217:121–6.

190. Weiland LC, Kluge K, Kutter APN, Kronen PW. Clinical evaluation of intranasal medetomidine-ketamine and medetomidine-S(+)-ketamine for induction of anaesthesia in rabbits in two centres with two different administration techniques. Vet Anaesth Analg 2017;44:98–105.